GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (NAS:WVE) » Definitions » EPS (Basic)

WVE (WAVE Life Sciences) EPS (Basic) : $-0.83 (TTM As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is WAVE Life Sciences EPS (Basic)?

WAVE Life Sciences's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was $-0.29. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.83.

WAVE Life Sciences's EPS (Diluted) for the three months ended in Mar. 2025 was $-0.29. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.84.

WAVE Life Sciences's EPS without NRI for the three months ended in Mar. 2025 was $-0.29. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -0.89.

During the past 3 years, the average EPS without NRI Growth Rate was 31.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 36.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 0.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, WAVE Life Sciences's highest 3-Year average EPS without NRI Growth Rate was 45.70% per year. The lowest was -149.80% per year. And the median was 0.60% per year.


WAVE Life Sciences EPS (Basic) Historical Data

The historical data trend for WAVE Life Sciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences EPS (Basic) Chart

WAVE Life Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.82 -2.36 -2.05 -0.54 -0.70

WAVE Life Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.25 -0.47 0.18 -0.29

WAVE Life Sciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

WAVE Life Sciences's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-97.008-0)/138.277
=-0.70

WAVE Life Sciences's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-46.878-0)/162.527
=-0.29

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WAVE Life Sciences  (NAS:WVE) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


WAVE Life Sciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


WAVE Life Sciences Business Description

Traded in Other Exchanges
Address
7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Executives
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Paul Bolno director, officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chris Francis officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Kyle Moran officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Chandra Vargeese officer: See Remarks C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Michael A. Panzara officer: Franchise Lead, Neurology 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Aik Na Tan director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
David G Gaiero officer: Interim CFO 733 CONCORD AVENUE, C/O WAVE LIFE SCIENCES USA, INC., CAMBRIDGE MA 02138
Gregory L. Verdine director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Amy Pott director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Heidi L Wagner director C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138